The treatment strategy for congenital adrenal hyperplasia is burdensome and had not changed in more than 70 years until the ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

Highlight,Sector Focus,: BridgeBio Pharma operates in the biopharmaceutical sector, with a focus on genetic conditions and oncology.,Insider Actions,: Notable insider share transactions have been ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report) today and set a price target of ...